News
Back to News
Formulary Update Bulletin: Effective April 1, 2024
February 2, 2024
The changes in this bulletin apply to all groups that use OptumRx Lowest Net Cost (LNC) Formulary.
These changes include decisions that occurred as a result of our November 2023 Pharmacy and Therapeutics Committee (P&T) meeting. Members negatively impacted by one of these changes will be sent a letter in February.
Formulary Update Additions
These drugs will be added to the formulary effective April 1, 2024.
Product | Management Programs | Formulary Status |
|---|---|---|
| Brixadi | Quantity Limit | Non-Preferred |
| Vanflyta | Prior Authorization | Non-Preferred |
Moving to Nonformulary Status
The following drugs will move to nonformulary status, effective April 1, 2024. The products listed in this section have alternatives available on the formulary, many times at a lower cost to the member. Note: some covered alternatives may require prior authorization (PA).
- Aubagio
- Daliresp
- Feraheme
- Latuda
- Mirvaso
- Prezista
- Pylera
- Selzentry
- Suprep Bowel Prep Kit
- Sutent